Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Premium Services
Financial News
Latest
Earnings
Guidance
Dividends
M&A
Buybacks
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Small-Cap
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Unusual Options Activity Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

Comments

Loading...

Viatris Stock News

VTRSNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$11.68

0.030.26%

Last update: Dec 15, 3:01 PM

News

Earnings Options Guidance Dividends Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Latest Viatris Stock News | NASDAQ:VTRS | Benzinga

Get the latest news on Viatris stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Viatris performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, December 09, 2025

Barclays Initiates Coverage On Viatris with O...
Benzinga Newsdesk

Monday, December 08, 2025

Reported Saturday, Viatris Enters Definitive ...
Benzinga Newsdesk

Monday, December 01, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor

Friday, November 28, 2025

These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday
Piero Cingari

Friday, November 14, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor

Tuesday, November 11, 2025

Wall Street Pauses, Silver Reclaims $50 With Shutdown End In Sight: What's Moving Markets Tuesday?
Piero Cingari

Thursday, November 06, 2025

Viatris shares are trading lower after the co...
Benzinga Newsdesk
Viatris Raises FY2025 Adj EPS Guidance from $...
Benzinga Newsdesk
Viatris Q3 Adj. EPS $0.67 Beats $0.62 Estimat...
Benzinga Newsdesk
Earnings Scheduled For November 6, 2025
Benzinga Insights

Thursday, October 30, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor

Tuesday, October 28, 2025

Viatris And Locus Biosciences Enter Research ...
Benzinga Newsdesk

Wednesday, October 15, 2025

Truist Securities Initiates Coverage On Viatr...
Benzinga Newsdesk

Thursday, October 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
Vandana Singh

Wednesday, September 17, 2025

Mapi Pharma Enrolls First Patient Into Phase ...
Benzinga Newsdesk

Thursday, September 04, 2025

FDA Announces Discontinuation Of Manufacture ...
Benzinga Newsdesk

Tuesday, August 26, 2025

S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
Chris Katje

Saturday, August 16, 2025

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Bibhu Pattnaik

Wednesday, August 13, 2025

Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit
Vandana Singh

Tuesday, August 12, 2025

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
Vandana Singh

Monday, August 11, 2025

Viatris Receives FDA Approval For First Gener...
Benzinga Newsdesk

Thursday, August 07, 2025

Viatris shares are trading higher after the c...
Benzinga Newsdesk
Viatris Affirms FY2025 Adj EPS Guidance of $2...
Benzinga Newsdesk
Viatris Q2 Adj. EPS $0.62 Beats $0.55 Estimat...
Benzinga Newsdesk
Earnings Scheduled For August 7, 2025
Benzinga Insights

Friday, August 01, 2025

Viatris To Present Five Abstracts From Phase ...
Benzinga Newsdesk

Friday, July 25, 2025

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
Vandana Singh

Friday, July 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Vandana Singh
Viatris shares are trading lower after the co...
Benzinga Newsdesk
Viatris' Phase 3 Study Of MR-139 For Blephari...
Benzinga Newsdesk

Thursday, July 10, 2025

NY State Attorney General Letetia James Posts...
Benzinga Newsdesk

Tuesday, July 08, 2025

FDA Discontinues Mylan Pharmaceuticals' Potas...
Benzinga Newsdesk

Thursday, June 26, 2025

Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Vandana Singh
Viatris And Opus Genetics Say VEGA-3 Phase 3 ...
Benzinga Newsdesk
Viatris And Opus Genetics Report Top-Line Res...
Benzinga Newsdesk

Friday, June 20, 2025

Nintedanib Viatris Received Positive Opinion ...
Benzinga Newsdesk

Friday, June 06, 2025

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Vandana Singh
Goldman Sachs Initiates Coverage On Viatris w...
Benzinga Newsdesk
Theravance, Mylan Reach Settlement With Eugia...
Benzinga Newsdesk

Thursday, May 22, 2025

Peering Into Viatris's Recent Short Interest
Benzinga Insights

Thursday, May 08, 2025

Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars
Vandana Singh
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Chandrima Sanyal
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Viatris shares are trading higher after the c...
Benzinga Newsdesk
Viatris Raises FY2025 Adj EPS Guidance from $...
Benzinga Newsdesk
Viatris Q1 Adj. EPS $0.50 Beats $0.49 Estimat...
Benzinga Newsdesk
Viatris Reports Phase 3 Results for Low-Dose ...
Benzinga Newsdesk
Viatris Reports Phase 3 Results for Fast-Acti...
Benzinga Newsdesk
Earnings Scheduled For May 8, 2025
Benzinga Insights

Wednesday, May 07, 2025

Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
Piero Cingari

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Novo Nordisk AS

Johnson & Johnson

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved